SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (13627)1/23/1998 12:36:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
P2, LGND has several miletones tied to PFE's development of Droloxifene and CP-366,156. I'm sure that an NDA filing for Droloxifene is one, but since the PFE alliance was an osteoporosis drug, I'm not sure how significant a milestone for an NDA for breast cancer would be. They may get a similar or larger payment for Droloxifene moving in Phase III for osteoporosis or CP-366,156 moving into Phase II for osteoporosis.



To: Proton who wrote (13627)1/23/1998 8:16:00 AM
From: tonyt  Respond to of 32384
 
> Re: "... the info wasn't all that good" May be an Understatement

Why do I get the feeling that somehow this is actually good news for LGND. :-)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News